Lysophosphatidylinositol-glucagon like peptide 1 crosstalk in metabolic diseases
| dc.contributor.author | Paternoster, Silvano | |
| dc.contributor.supervisor | Marco Falasca | en_US |
| dc.date.accessioned | 2020-11-13T06:22:53Z | |
| dc.date.available | 2020-11-13T06:22:53Z | |
| dc.date.issued | 2020 | en_US |
| dc.identifier.uri | http://hdl.handle.net/20.500.11937/81689 | |
| dc.description.abstract |
This PhD thesis discusses the study of a novel class of drugs for the treatment of metabolic diseases. We have characterized the pharmacology and biology of the lipid Oleoyl-lysophosphatidylinositol (Oleoyl-LPI), and we show that some synthetic molecules mimicking its structure, are efficient glucagon-like peptide-1 (GLP-1) secreting drugs in vitro and in vivo in diabetic mice. We have also dissected the pharmacology of Cannabis-derived drugs and demonstrated that they can also modulate GLP-1 secretion. | en_US |
| dc.publisher | Curtin University | en_US |
| dc.title | Lysophosphatidylinositol-glucagon like peptide 1 crosstalk in metabolic diseases | en_US |
| dc.type | Thesis | en_US |
| dcterms.educationLevel | PhD | en_US |
| curtin.department | School of Pharmacy and Biomedical Sciences | en_US |
| curtin.department | Curtin Health Innovation Research Institute | en_US |
| curtin.accessStatus | Open access | en_US |
| curtin.faculty | Health Sciences | en_US |
| curtin.contributor.orcid | Paternoster, Silvano [0000-0003-1224-0258] | en_US |